PATENT CLAIM ANALYSIS

Application Number: 16138204
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-06
Patent Classification: ["424", "185100"]

Abstract:
The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.

Claim (Index 1):
A recombinant polypeptide comprising an amino acid sequence having at least 99% sequence identity to the polypeptide of SEQ ID NO: 1, wherein\n i. the recombinant polypeptide is acidic as determined by isoelectric point (pI); ii. the pI of the recombinant polypeptide is lower than the pI of SEQ ID NO: 1; and iii. aspartic acid, glutamic acid and leucine are each independently present in an amount greater than, or equal to, the amount of any other amino acid residue present within the recombinant polypeptide sequence.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 97.0
- Lexical Diversity: 1.61905
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16138224', '15854906', '16138212', '16138219', '12671356']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8191484034597684
- 35 USC 102 Novelty (BERT): 0.606692805225814
- Combined Prediction Score: 0.7979028436363729
- Mean Citation Score: 548.173012
- Max Citation Score: 632.3406
- Similarity Product: 467.67650886869416

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test